If the company is successful with the offering, it will have about $60 million in new equity, he said.
Chattem plans to use some of the proceeds from the offering to retire the remaining $38.5 million of bank debt from its purchase of Selsun Blue, Taylor said. The company bought Selsun Blue, a medicated dandruff shampoo, from Abbott Laboratories (ABT, news, msgs) earlier this year for $75 million plus inventories.
After the bank debt is paid, Chattem will have about $20 million in cash remaining from the offering and about $20 million of cash sitting on its balance sheet, Taylor said. The available cash positions Chattem well for potential future acquisitions, he said. Although he declined to be specific, Taylor said there have been some public announcements about companies putting brands on the selling block. It's difficult to say if Chattem will do anything in the near term, he said.
scheint doch nur eine momentane Konsilidierung
|
Thread abonnieren
